A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma
A phase 2 trial of Safusidenib in glioma & glioblastoma, run by Daiichi Sankyo Co., Ltd., active and no longer recruiting.
Overview
A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma is a phase 2 interventional study registered as NCT04458272 by Daiichi Sankyo Co., Ltd., with 25 participants enrolled, started 2020-07-08 and due to reach its primary completion in 2023-03-10. Interventions recorded: DS-1001b.
Similar pages
not linked directly; found by shared links- TrialFirst-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Shares Daiichi Sankyo and the tag pipeline.
- TrialA First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Shares Daiichi Sankyo and the tag pipeline.
- TrialMaximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Shares Glioma & glioblastoma and the tag pipeline.
- TrialA Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
Shares Glioma & glioblastoma and the tag pipeline.
- TrialA Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
Shares Glioma & glioblastoma and the tag pipeline.
- TrialA Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
Shares Glioma & glioblastoma and the tag pipeline.
- TrialStudy of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas
Shares Glioma & glioblastoma and the tag pipeline.
- TrialInjection of Active Allogeneic Natural Killer Cells in Patients With Gliomas
Shares Glioma & glioblastoma and the tag pipeline.